← All trials
NCT04528290
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2020
- Primary completion
- Nov 25, 2020
- Completion date
- Dec 10, 2020
- First posted
- Aug 27, 2020
- Last posted
- Aug 27, 2020
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CelgeneLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.